Omega-3 Fatty Acid-Rich Parenteral Nutrition: Is It a Double-Edged Sword?

J Pediatr Gastroenterol Nutr. 2015 Oct;61(4):469-71. doi: 10.1097/MPG.0000000000000863.

Abstract

Parenteral nutrition (PN) has been strongly associated with intestinal failure-associated liver disease. Cholestasis, liver steatosis, and liver fibrosis are features of this liver injury, which can progress to end stage liver disease. Omega-3 fatty acid rich PN has been shown to alleviate cholestasis and steatosis. There have been reports although suggesting that it may not be able to arrest or reverse the progression to liver fibrosis. In this article, we develop a hypothesis of the mechanism of how Ω-3 fatty acid rich PN may influence the progression of fibrosis.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Cholestasis, Intrahepatic / etiology
  • Cholestasis, Intrahepatic / metabolism
  • Cholestasis, Intrahepatic / prevention & control
  • Diacylglycerol O-Acyltransferase / antagonists & inhibitors*
  • Diacylglycerol O-Acyltransferase / metabolism
  • Fat Emulsions, Intravenous / adverse effects*
  • Fat Emulsions, Intravenous / metabolism
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Acids, Omega-3 / adverse effects*
  • Fatty Acids, Omega-3 / metabolism
  • Humans
  • Liver / enzymology
  • Liver / metabolism
  • Liver Cirrhosis / enzymology
  • Liver Cirrhosis / etiology*
  • Liver Cirrhosis / metabolism
  • Models, Biological*
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / prevention & control*
  • Parenteral Nutrition / adverse effects*
  • Triglycerides / metabolism

Substances

  • Fat Emulsions, Intravenous
  • Fatty Acids, Omega-3
  • Triglycerides
  • Diacylglycerol O-Acyltransferase